Intravitreal Ranibizumab in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa

Artunay, Özgür; Yüzbaşıoğlu, Erdal; Rasier, Rıfat; Şengül, Elvan Alper; Bahçecioğlu, Halil

doi:10.1089/jop.2009.0089

Cited by 43 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adverse effects of intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs in eyes with RP have not been reported, whether this therapy was to treat CNV [2, 3] or cystoid macular edema [10, 11]. In our patient, mottled fluorescence with a mixture of hypo- and hyperpigmentation appeared temporal to the macula after disappearance of hemorrhage.…”

Section: Discussionmentioning

confidence: 76%

Polypoidal choroidal vasculopathy in a case with retinitis pigmentosa

et al. 2012

View full text Add to dashboard Cite

There have been no reports describing polypoidal choroidal vasculopathy (PCV) in eyes with retinitis pigmentosa (RP). A 63-year-old woman who had been diagnosed as having RP was referred to us because of sudden onset of blurred vision in her right eye. Funduscopic examination revealed retinal findings typical of RP in both eyes. The macular area of the right fundus showed polypoidal lesions with massive hemorrhages. Fluorescein angiography and indocyanine green angiography showed multiple polypoidal lesions. Optical coherence tomography showed a large hemorrhagic retinal pigment epithelial (RPE) detachment and polypoidal lesions. The PCV subsided after three applications of anti-vascular endothelial growth factor (VEGF) therapy and a single application of photodynamic therapy, but “mottled lesions” with hyper- and hypofluorescence appeared temporal to the macula after disappearance of hemorrhage. We present a case of PCV in an eye with RP. Further studies are necessary to clarify whether anti-VEGF therapies could affect RPE status in eyes with RP.

show abstract

Section: Discussionmentioning

confidence: 76%

Polypoidal choroidal vasculopathy in a case with retinitis pigmentosa

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In case report of Mustafa et al, a single unilateral intravitreal injection of aflibercept was given to a patient with RP-associated CMO. Improvement in both visual acuity and macular thickness was seen at 1 month post-injection as well as maintenance of this improvement documented at 6 months [19].…”

Section: Introductionmentioning

confidence: 78%

Effects of intravitreal aflibercept (Eylea) in the treatment of bilateral cystoid macular edema in retinitis pigmentosa: A case report

et al. 2019

View full text Add to dashboard Cite

Introduction. The aim of the study was to evaluate the effects of intravireal injections of aflibercept (Eylea) on bilateral cystoid macular edema in a patient with retinitis pigmentosa. Material and Methods. A 17-year-old man presented with a moderate bilateral decrease of visual acuity (0.3) and ocular examination was performed. Optical coherence tomography imaging was performed and cystoid macular edema was detected in both eyes. Due to disease progression in a short period of time, intravitreal repeated injections of aflibercept (Eylea) were initiated according to recent clinical reports. Results. The initial values of cystoid macular edema before intravitreal therapy were 248 ?m in the right and 237 ?m in the left eye; they increased slowly in next several weeks. Four bilateral repeated doses of intravitreal aflibercept injections at 6-week intervals were given in local anesthesia. The patient reported a subjective improvement, and his visual acuity was 4/10 in both eyes. Objectively, the macular edema decreased at week 24, reaching 173 ?m in the right and 188 ?m in the left eye. Conclusion. There are few literature reports on the possible effects of intravitreal aflibercept injections in the treatment of retinitis pigmentosa-related cystoid macular edema. In our study, bilateral macular edema in a patient with retinitis pigmentosa has improved significantly after four consecutive treatments. Further studies are necessary with a larger sample size and longer follow-up period to obtain information on the role and safety of intravitreal drugs for cystoid macular edema in retinitis pigmentosa. This article has been corrected. Link to the correction <a href="http://dx.doi.org/10.2298/MPNS1910326E">10.2298/MPNS1910326E</a>

show abstract

“…Numerous reports have discussed medical and surgical treatments. Some medical treatments, such as oral carbonic anhydrase inhibitor acetazolamide,11–13 intravitreous triamcinolone,14 and antivascular endothelial growth factor agents,15 have been reported; however, most seem to only temporarily affect the CME. However, some studies have reported successful results with vitrectomy combined with ILM removal in some RP cases with CME 6,16.…”

Section: Discussionmentioning

confidence: 99%

Tangential vitreous traction: a possible mechanism of development of cystoid macular edema in retinitis pigmentosa

Takezawa¹,

Tetsuka²,

Kakehashi³

2011

OPTH

View full text Add to dashboard Cite

We report the possible mechanism of development of cystoid macular edema (CME) in retinitis pigmentosa (RP) in the case of a 68-year-old woman with RP and CME in the right eye and resolving CME in the left eye. Spectral domain optical coherence tomography showed CME and posterior vitreoschisis in the nasal quadrant of the fundus without a posterior vitreous detachment (PVD). This vitreous pathology suggested bilateral thickening and shrinkage of the posterior vitreous cortex. In the right eye, CME was evident with no vitreofoveal separation. However, in the left eye, minimal change was seen in the CME associated with a focal shallow PVD over the fovea. The best-corrected visual acuity (BCVA) in the left eye increased to 0.3 from 0.15 7 years after the first visit. Tangential vitreous traction on the macula may have caused the CME in the right eye. The shallow PVD over the fovea might have released the tangential vitreous traction from the fovea, induced spontaneous resolution of the CME, and improved the BCVA in the left eye.

show abstract

Intravitreal Ranibizumab in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa

Abstract: This investigation indicated that IVR may provide a new therapeutic approach for the treatment of CME secondary to RP. No adverse event was found to be associated with the treatment. Continued experience with IVR in this population will help establish its longer-term efficacy.

Cited by 43 publications

References 33 publications

Polypoidal choroidal vasculopathy in a case with retinitis pigmentosa

Polypoidal choroidal vasculopathy in a case with retinitis pigmentosa

Effects of intravitreal aflibercept (Eylea) in the treatment of bilateral cystoid macular edema in retinitis pigmentosa: A case report

Tangential vitreous traction: a possible mechanism of development of cystoid macular edema in retinitis pigmentosa

Contact Info

Product

Resources

About